October 2026
1. FAGGIANI I, Tuttle C, Danese S, Peyrin-Biroulet L, et al
   Antibiotic-Refractory Chronic Pouchitis After Ileal Pouch-Anal Anastomosis: Current and Emerging Therapeutic Strategies.
   Drugs. 2026;86:1577-1597.
   

   >> Share

   
   June 2026
2. ROSEIRA J, Hupe M, Yuan Y, Magro F, et al
   Oral Gut-Restricted Targeted Therapy for IBD: A Pipeline Review.
   Drugs. 2026;86:779-795.
   

   >> Share

   
   May 2025
3. NARDONE OM, Vuyyuru SK, Yuan Y, Hanzel J, et al
   Differentiating IL-23 Inhibitors in Crohn's Disease.
   Drugs. 2025 May 5. doi: 10.1007/s40265-025-02183.
   

   >> Share

   
   November 2024
4. NIELSEN OH, Hammerhoj A, Ainsworth MA, Gubatan J, et al
   Immunogenicity of Therapeutic Antibodies Used for Inflammatory Bowel Disease: Treatment and Clinical Considerations.
   Drugs. 2024 Nov 13. doi: 10.1007/s40265-024-02115.
   

   >> Share

   
   September 2024
5. KITSOU K, Kokkotis G, Rivera-Nieves J, Bamias G, et al
   Targeting the Sphingosine-1-Phosphate Pathway: New Opportunities in Inflammatory Bowel Disease Management.
   Drugs. 2024 Sep 26. doi: 10.1007/s40265-024-02094.
   

   >> Share

   
   February 2024
6. SHIRLEY M
   Etrasimod: First Approval.
   Drugs. 2024;84:247-254.
   

   >> Share

   
   September 2023
7. BLAIR HA
   Ritlecitinib: First Approval.
   Drugs. 2023;83:1315-1321.
   

   >> Share

   
   July 2023
8. GISBERT JP, Chaparro M
   Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's Disease.
   Drugs. 2023 Jul 28. doi: 10.1007/s40265-023-01916.
   

   >> Share

   
   
9. VUYYURU SK, Shackelton LM, Hanzel J, Ma C, et al
   Targeting IL-23 for IBD: Rationale and Progress to Date.
   Drugs. 2023;83:873-891.
   

   >> Share

   
   
10. KEAM SJ
    Mirikizumab: First Approval.
    Drugs. 2023;83:1045-1052.
    

    >> Share

    
    May 2023
11. SKJELLERUDSVEEN BM, Skoie IM, Dalen I, Grimstad T, et al
    The Effect of Biological Treatment on Fatigue in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
    Drugs. 2023 May 23. doi: 10.1007/s40265-023-01888.
    

    >> Share

    
    March 2023
12. NUNEZ P, Quera R, Yarur AJ
    Safety of Janus Kinase Inhibitors in Inflammatory Bowel Diseases.
    Drugs. 2023;83:299-314.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share